Bayer AG v. Aurobindo Pharma: Cardiovascular Patent Suit Dismissed Without Prejudice
Bayer AG and Janssen Pharmaceuticals sued Aurobindo Pharma in Delaware over US10828310B2, a patent covering reduction of cardiovascular event risk. After 203 days of litigation, plaintiffs voluntarily dismissed all claims without prejudice — leaving the door open for future enforcement action.
Bayer’s cardiovascular patent action ends before substantive merits ruling
Bayer AG, alongside co-plaintiff Janssen Pharmaceuticals, Inc., filed suit against Aurobindo Pharma Ltd. on 21 May 2025 in the District of Delaware before Judge Richard G. Andrews. The complaint asserted infringement of US10828310B2, a patent directed to reducing the risk of cardiovascular events, in what is consistent with a Hatch-Waxman ANDA challenge brought in response to Aurobindo’s efforts to market a generic version of a cardiovascular therapy.
On 10 December 2025, the plaintiffs filed a notice of voluntary dismissal pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i), dismissing all claims without prejudice. A Rule 41(a)(1)(A)(i) dismissal at this procedural stage — before the defendant files an answer or a motion for summary judgment — requires no court order and takes effect immediately upon filing. The without-prejudice designation means Bayer and Janssen retain the legal right to refile the same claims at a later date.
The 203-day duration suggests the case did not reach substantive discovery or claim construction before resolution. The public record does not disclose the commercial driver behind the dismissal — possibilities include an out-of-court settlement, a licensing arrangement, a decision to await PTAB proceedings, or a strategic reassessment of the litigation posture. The absence of a with-prejudice stipulation is commercially significant: Aurobindo faces residual enforcement risk for as long as US10828310B2 remains in force.
Filing to Voluntary dismissal in 203 days
203 days — resolved before trial; shorter than median ANDA patent case in Delaware
Voluntarily dismissed: what a Rule 41 without-prejudice exit means
Rule 41(a)(1)(A)(i): unilateral dismissal, no court sign-off needed
Fed. R. Civ. P. 41(a)(1)(A)(i) allows a plaintiff to dismiss as of right before the defendant serves an answer or a motion for summary judgment. The notice is self-executing — it takes effect on filing. No judicial approval is required, and the docket will show ‘dismissed’ without any merits adjudication. This mechanism is commonly deployed when parties reach a commercial resolution they prefer to keep confidential.
Procedural exit — no merits rulingWithout prejudice: re-filing remains available to Bayer
A dismissal without prejudice does not extinguish the underlying patent claims. Bayer and Janssen may refile suit on US10828310B2 against Aurobindo — or any other generic entrant — provided the statute of limitations and patent term permit. The public record is silent on whether a settlement, licence, or consent judgment was reached privately. Parties and counsel sometimes pair a without-prejudice dismissal with a confidential side agreement that effectively resolves the dispute.
Claims preserved — refiling possibleAurobindo faces residual risk despite the dismissal
Because the dismissal is without prejudice, Aurobindo cannot treat the case as finally resolved from a freedom-to-operate perspective. If no confidential licence or consent decree accompanies the dismissal, Aurobindo’s commercial launch of any product touching US10828310B2 remains subject to re-litigation risk. Generic manufacturers in this position typically seek a covenant not to sue or a formal licence before proceeding with launch.
Residual infringement riskPatent lives on — market uncertainty for cardiovascular generics
US10828310B2 survives this dismissal fully intact and enforceable. Other generic manufacturers seeking to enter the cardiovascular risk-reduction market should treat the patent as an active blocking asset. The voluntary dismissal without prejudice, when paired with no public licence grant, typically signals that the innovator has not surrendered its enforcement position. FTO analysis against this patent remains commercially necessary for any competitor in this space.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bayer AG | Company | Pharmaceutical innovator — holder of US10828310B2 covering cardiovascular risk-reduction therapiesSearch in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Aurobindo Pharma Ltd. — Indian generic pharmaceutical manufacturer seeking U.S. market entrySearch in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bayer AGSearch in Eureka ↗ |
| Defendant counsel | R. Touhey Myer. | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and specifies withdrawal without prejudice — the most consequential phrase in the filing. Because no answer had been served, the dismissal is self-executing and carries no res judicata effect. Neither patent validity nor infringement was adjudicated. For Aurobindo, the practical effect depends entirely on whether a confidential ancillary agreement exists; without one, the commercial and legal risk profile against US10828310B2 is unchanged.
US10828310B2 — Reducing the risk of cardiovascular events
US10828310B2 was filed under application number US16/264032 and covers therapeutic methods or compositions directed to reducing the risk of cardiovascular events — a high-value clinical indication that typically encompasses stroke, myocardial infarction, and related acute cardiovascular outcomes. The patent is held by Bayer AG and was asserted jointly with Janssen Pharmaceuticals, suggesting a co-ownership or licensing structure common in pharmaceutical co-development arrangements. Its issuance under the B2 designation confirms it has passed substantive examination.
Cardiovascular indication patents are among the most commercially defended assets in the pharmaceutical sector, given the large patient population and multi-billion-dollar market size. The assertion of this patent against an ANDA filer like Aurobindo is consistent with standard Hatch-Waxman enforcement practice, where innovators file infringement suits to trigger the 30-month regulatory stay that delays generic approval. Competitors developing cardiovascular generics, biosimilars, or combination products in adjacent indication spaces should treat US10828310B2 as a material blocking asset until expiry or invalidation.
Should you run an FTO analysis against US10828310B2?
Any company developing a generic, branded, or combination cardiovascular therapy that reduces the risk of cardiovascular events should conduct freedom-to-operate analysis against US10828310B2 before filing an ANDA, commencing clinical trials, or entering the U.S. market. The patent’s survival through this litigation — and Bayer’s demonstrated willingness to enforce it in Delaware — elevates it to a tier-one blocking asset for the cardiovascular indication space.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim scope against product candidates in real time, identify prosecution history disclaimers that may narrow enforceability, and surface continuation applications that could extend the patent family’s reach. For teams monitoring Hatch-Waxman exposure across a cardiovascular pipeline, Eureka provides automated citation mapping and claim-by-claim landscape analysis to support informed go/no-go decisions.
Run a freedom-to-operate analysis on US10828310B2 to assess your product’s exposure
Run FTO in Eureka →Similar cardiovascular patent infringement cases in Delaware District Court
Explore related Hatch-Waxman patent infringement cases involving cardiovascular therapies litigated in Delaware District Court with comparable procedural outcomes.
What this case signals for the cardiovascular generic drug IP landscape
A without-prejudice exit in Delaware preserves Bayer’s enforcement options and leaves Aurobindo’s market path legally uncertain.
Without-prejudice dismissals preserve optionality — track the patent, not just the case
US10828310B2 remains in force after this dismissal. Any company developing or commercialising a cardiovascular event risk-reduction therapy should monitor this patent for continuations, reissues, and new enforcement actions. A closed docket does not signal a cleared path to market.
Rule 41 exits often mask private commercial agreements — read the silence carefully
The absence of any public settlement or consent decree in this case is consistent with a confidential licence or co-existence agreement. IP teams tracking Bayer’s enforcement posture should cross-reference ANDA Orange Book listings and any subsequent NDA/ANDA approval filings to infer whether a commercial resolution was reached.
Bayer v Aurobindo — key questions answered
The plaintiffs filed a Rule 41(a)(1)(A)(i) notice dismissing all claims without prejudice on 10 December 2025. No merits ruling was issued. Without prejudice means Bayer and Janssen retain the right to refile the same patent infringement claims against Aurobindo at a future date, subject to patent term and any private agreements between the parties.
Bayer AG and Janssen Pharmaceuticals asserted US10828310B2 (application number US16/264032), a patent directed to reducing the risk of cardiovascular events. The case is consistent with a Hatch-Waxman ANDA infringement action filed in the District of Delaware.
The dismissal without prejudice does not resolve the underlying patent dispute on the merits. Aurobindo’s freedom to launch depends on FDA approval status, whether a 30-month Hatch-Waxman stay has expired, and whether a confidential licence or consent decree exists. Absent such an agreement, US10828310B2 remains an active enforcement risk.
The public record does not disclose the reason. Common drivers for without-prejudice dismissals in ANDA litigation include confidential licence agreements, negotiated launch-date stipulations, strategic decisions to pursue PTAB proceedings, or commercial settlements. The 203-day case duration suggests resolution occurred well before trial or substantive motions practice.
Yes. A voluntary dismissal without prejudice does not affect patent validity or enforceability. US10828310B2 remains an active, issued U.S. patent. Bayer retains full rights to assert it against Aurobindo or any other party whose product falls within the claim scope, for the remaining term of the patent.
PatSnap Eureka searches patents and litigation data to answer instantly.